Neurodegenerative funding launched for Scottish researchers

A new fund has been launched in Scotland to help boost the nation’s neurodegenerative research capacity.

The funding pool is being administered by the University of St Andrews and will see The Scottish Government and the RS Macdonald Charitable Trust each contribute £75,000 of funding this year.

Researchers from across Scotland’s universities will be able to apply for seed-corn grants of up to £15,000 to support clinically relevant research into conditions – including Alzheimer’s, Motor Neurone Disease, Parkinson’s and Multiple Sclerosis.

The fund will provide an opportunity for researchers working in different academic centres with the chance to test out ideas that could lead to future funding or development of further collaborative working.

Applications will be assessed by an expert panel of clinicians, academic researchers and lay representatives chaired by University of St Andrews Professor Frank Gunn-Moore, who established and initially chaired the Alzheimer’s Research UK network for Scotland.

Health Secretary Jeane Freeman said: “We launched the consultation for the first Scottish National Action Plan on Neurological Conditions at the end of last year as we work to transform care for people affected by neurological conditions and raise awareness more broadly.

“The plan covers common themes that are important to people living with neurological conditions, ranging from everyday conditions such as migraines to rare and life-limiting illnesses such as Motor Neurone Disease and Huntington’s Disease.”

Professor Frank Gunn-Moore from the University of St Andrews added: “One of the best things about working in Scotland is that our universities and research institutions have always worked together: this is imperative when trying to tackle these diseases.

“This type of seed-corn funding is imperative for researchers to try out new ideas and concepts, and we are exceptionally grateful to the Scottish Government and the RS MacDonald Charitable Trust.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Related news

Pharma industry invests £381m in UK R&D activities

The pharmaceutical industry has invested £381.2 million on R&D activities in the UK during 2019, up from £377.3 million in 2018, according to new...

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...